Don Kennedy

– Don Kennedy, former FDA commissioner and editor-in-chief of Science. – ‘The FDA needs more resources should be clear, is the qualifications of the staff that they process the year long to make it together, and the depth of analysis its its conclusion wrote What makes this report so extraordinary: FDA. Mission is at risk for lack of support for its scientific capabilities . ‘.

Comments on the report:’Over the past decade, complex scientific advances, globalization and challenging new safety issues combined to multiply the functions of the FDA As this new report makes clear: our expectations can not exceed the resources we give FDA fulfill its mission in this context is certainly better ‘. Mark McClellan, former FDA commissioner and chairman of the new Reagan – Udall Institute.

About GentiumGentium SpA is a biopharmaceutical company extract in the research, discovery and development of pharmaceuticals derive in DNA from natural resources , and treating medications is synthetic derivatives of focused, and for prevents a variety of vascular illness and conditions related to cancer and cancer therapy. Defibrotide, the society ‘s reference substance an investigational, that orphan medicinal product status has granted prevent from the U.S. Food and Drug Administration and the EMEA and treat statements designation from the FDA in the treatment of severe VOD in recipients stem cell transplanta. – Note Regarding Forward Looking Statements.